◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 6660

AIM Vaccine Co., Ltd. (6660) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

AIM Vaccine Co., Ltd. (6660) operates in the Biotechnology industry and is headquartered in Beijing, China with about 1,466 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 6660 reported CNY 1.2B in revenue and (CNY 676M) in net income.

AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People's Republic of China and internationally.

Interactive charts & full statements →

6660 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 1.2BCNY 1.3BCNY 1.2BCNY 1.3B
Gross ProfitCNY 760MCNY 954MCNY 901MCNY 1.0B
Operating Income (EBIT)(CNY 192M)(CNY 211M)(CNY 451M)(CNY 381M)
Net Income(CNY 676M)(CNY 277M)(CNY 1.3B)(CNY 320M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6660 Free Cash Flow History

6660 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 6.5BCNY 7.3BCNY 7.3BCNY 8.9B
Total LiabilitiesCNY 3.6BCNY 3.7BCNY 3.4BCNY 3.0B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6660 viewer.

Other Companies in Biotechnology

← 6659All “0-9” companies6661 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.